Literature DB >> 11536711

Enantioselective autocatalysis. III. Configurational and conformational studies on a 1,4-benzodiazepinooxazole derivative.

B L Miller1, W A Bonner.   

Abstract

We report here on configurational and conformational studies undertaken on the bromofluoro-1,4-benzodiazepinooxazole derivative I, which has previously been found capable of undergoing total spontaneous resolution under racemizing conditions. Due to its bridgehead N-atom I may exist in any of four diastereomeric forms, CRNR (or CSNS) and CRNS (or CSNR). Molecular mechanics calculations revealed that in their lowest energy conformations the CRNR (or CSNS) diastereomers were favored over the CRNS (or CSNR) diastereomers by some 3.42 kcal/mol, while semi-empirical quantum mechanical calculations indicated heats of formation also favoring the CRNR (or CSNS) diastereomers by 3.83 kcal/mol. The 1H NMR spectra of the three crystalline modifications (alpha, beta and gamma) of I were examined in acetone, and found to be identical. These data, combined with the results of the above calculations, suggest that I exists in methanol or methanol-acetone solutions as the CRNR (or CSNS) enantiomer prior to its racemization.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 11536711     DOI: 10.1007/bf01582023

Source DB:  PubMed          Journal:  Orig Life Evol Biosph        ISSN: 0169-6149            Impact factor:   1.950


  1 in total

1.  Enantioselective autocatalysis. II. Racemization studies on a 1,4-benzodiazepinooxazole derivative.

Authors:  W A Bonner
Journal:  Orig Life Evol Biosph       Date:  1995-08       Impact factor: 1.950

  1 in total
  2 in total

1.  Enantioselective autocatalysis. IV. Implications for parity violation effects.

Authors:  W A Bonner
Journal:  Orig Life Evol Biosph       Date:  1996-02       Impact factor: 1.950

2.  Enantioselective autocatalysis. V. The spontaneous resolution of tri-o-thymotide.

Authors:  W A Bonner
Journal:  Orig Life Evol Biosph       Date:  1999-05       Impact factor: 1.950

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.